|
A.S. Botkina, M.I. Dubrovskaya, O.O. Khandamirova
Targeted therapy of atopic dermatitis in children
|
№8 / 2022
|
|
K.Yu. Zherebchikova, A.S. Ermolaeva, Yu.P. Sych, V.V. Fadeev
Features of the differential diagnosis of thyropathies induced by monoclonal antibodies: a clinical case
|
№4 / 2022
|
|
V.M. Tsvetov (1), I.S. Burashnikova (2), D.A. Sychev (3)
Possibility and prospects for the use of recombinant neutralizing monoclonal antibodies (bamlanivimab+etesevimab, sotrovimab) in patients with COVID-19
|
№12 / 2021
|
|
Ya.I. Ashikhmin (1), Yu.E. Azimova (1, 2)
Anti-CGRP monoclonal antibodies: focus on safety
|
№9 / 2019
|
|
I.V. Leshchenko (1, 2), T.Z. Buladzhova (2)
Severe bronchial asthma. Current diagnostic and treatment options
|
№5 / 2019
|
|
M.V. Ezhov
EVOLOUCUMAB - NEW HYPOLIDEPHEMIC AGENT FOR CARDIOVASCULAR RISK REDUCTION
|
№20 / 2017
|
|
M.I. Kurdina
MONOCLONAL ANTIBODIES IN THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
|
№7 / 2016
|
|
T.V. Korotaeva
CURRENT TREATMENT OF PSORIATIC ARTHRITIS
|
№20 / 2013
|
Русский
